Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Uveal Melanoma Recurrence After Fractionated Proton Beam Therapy: Comparison of Survival in Patients Treated With Reirradiation or With Enucleation

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [2];  [3];  [2]
  1. Department of Radiation Oncology, Regina Elena Research Institute, Rome (Italy)
  2. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA (United States)
  3. Retina Service, Massachusetts Eye and Ear Infirmary, Boston, MA (United States)

Purpose: To retrospectively compare survival in recurrent uveal melanoma, between patients treated by enucleation or by a second course of fractionated proton beam therapy (PBT). Methods and Materials: Tumor recurrence was documented in 73 patients treated with PBT for uveal melanoma. Of the patients, 31 received a second course of PBT and 42 underwent enucleation. The mean patient age was 56 and 61 years for those undergoing enucleation and those undergoing reirradiation, respectively. Both primary and recurrent tumors were larger in patients undergoing enucleation. Tumor location and the presence or absence of ciliary body involvement did not differ significantly between the groups. The median follow-up after enucleation and after re-treatment was 79 and 59 months, respectively. Cumulative rates of outcomes and differences in rates between the reirradiated and enucleation groups were calculated by the Cox proportional hazards model and the log-rank test, respectively. Results: The median survival duration in the enucleated and reirradiated groups was 42 and 90 months, respectively. The median time free of metastases was 38 months in enucleated patients and 97 months in reirradiated patients. At 5 years after enucleation and after reirradiation, the probability of overall survival was 36% and 63%, respectively (p = 0.040, log-rank test); the probability of freedom from metastases was 31% and 66%, respectively (p = 0.028, log-rank test). These differences persisted after adjustment for recurrent tumor largest diameter and volume at the time of reirradiation or enucleation. Conclusions: This retrospective analysis suggests that survival in reirradiated patients is not compromised by administration of a second course of PBT for recurrent uveal melanoma.

OSTI ID:
21491618
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 3 Vol. 79; ISSN IOBPD3; ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma
Journal Article · Tue Mar 14 23:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20793377

Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma
Journal Article · Mon May 01 00:00:00 EDT 2017 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22649918

The risk of enucleation after proton beam irradiation of uveal melanoma
Journal Article · Fri Sep 01 00:00:00 EDT 1989 · Ophthalmology (Rochester, Minnesota); (USA) · OSTI ID:5347862